Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Tango Therapeutics, Inc. due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Tango Therapeutics is expected to report a quarterly loss of $0.35 per share, reflecting a year-over-year change of -45.8% [3]. - Revenues are projected to be $6.19 million, down 68.9% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.62% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Tango Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.57% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Tango Therapeutics currently holds a Zacks Rank of 2, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Tango Therapeutics was expected to post a loss of $0.34 per share but actually reported a loss of -$0.36, resulting in a surprise of -5.88% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - Krystal Biotech, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $1.08 for the same quarter, indicating a year-over-year change of +25.6% [18]. - Revenues for Krystal Biotech are expected to be $90.5 million, up 28.8% from the previous year [18].

Company Overview - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2] - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related targets [2] Financial Announcement - Tango Therapeutics will report its second quarter 2025 financial results on August 5, 2025, before the U.S. financial markets open [1] - The company has stated that it will not hold a conference call following the financial results announcement [1]

Group 1 - Tango Therapeutics, Inc. (TNGX) closed at $5.93, with a 26.4% gain over the past four weeks, and a mean price target of $10.43 indicating a 75.9% upside potential [1] - The average of seven short-term price targets ranges from $8.00 to $13.00, with a standard deviation of $2.23, suggesting a potential increase of 34.9% to 119.2% from the current price [2] - Analysts show strong agreement on TNGX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for TNGX's current year has increased by 1% over the past month, with one estimate going higher and no negative revisions [12] - TNGX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide [14]

Core Insights - Tango Therapeutics has initiated the first patient dosing in a Phase 1/2 trial for TNG462 in combination with Revolution Medicines' daraxonrasib or zoldonrasib targeting MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer [1][2] - The trial aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of TNG462 in combination with the mentioned inhibitors [2] - TNG462 is a promising MTA-cooperative PRMT5 inhibitor, with monotherapy data expected in the second half of 2025, which may inform a registrational trial for pancreatic cancer in 2026 [3] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision cancer medicines [4] - The company employs the genetic principle of synthetic lethality to create therapies targeting critical cancer-related pathways [4]

Company Overview - Tango Therapeutics, Inc. (TNGX) shares increased by 7.5% to close at $5.16, with notable trading volume compared to typical sessions, and a total gain of 157.4% over the past four weeks [1][2] Pipeline Developments - The company recently dosed the first patient in the TNG456 phase I/II study targeting MTAP-deleted solid tumors, particularly glioblastoma, which has contributed to positive market sentiment regarding its pipeline of precision cancer medicines [2] Financial Expectations - Tango Therapeutics is projected to report a quarterly loss of $0.36 per share, reflecting a year-over-year decline of 50%, with expected revenues of $5.79 million, down 70.9% from the previous year [3] - The consensus EPS estimate for the quarter has been revised slightly higher in the last 30 days, indicating a potential for price appreciation if the trend continues [4] Industry Context - Tango Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where it holds a Zacks Rank of 3 (Hold) [5] - Another company in the same industry, Protagonist Therapeutics (PTGX), experienced a 1.1% decline in its stock price, with a monthly return of 17.5% [5][6]

Group 1 - U.S. stock futures are higher, with Dow futures gaining over 150 points [1] - Sarepta Therapeutics, Inc. shares fell 31.4% to $24.86 after suspending ELEVIDYS shipments and pausing ENVISION trial due to a second fatal liver failure in non-ambulatory Duchenne patients [1] Group 2 - KULR Technology Group, Inc. shares fell 21.9% to $0.8980 following a 1-for-8 reverse stock split [4] - Gold Royalty Corp. shares dipped 14.7% to $1.95, despite Canaccord Genuity initiating a Buy rating with a $3 price target [4] - Solid Biosciences Inc. shares fell 8% to $4.15, with JMP Securities reiterating a Market Outperform rating and maintaining a $15 price target [4] - Omada Health, Inc. shares declined 5.4% to $16.18 [4] - Repligen Corporation shares decreased 4% to $122.50 [4] - IonQ, Inc. shares slipped 3.2% to $36.65 [4] - Tango Therapeutics, Inc. shares declined 3.2% to $4.54 [4]

Summary of Tango Therapeutics Conference Call Company Overview - **Company**: Tango Therapeutics - **Industry**: Biotechnology, specifically focused on oncology and synthetic lethality Core Insights and Arguments - **Synthetic Lethality Platform**: Tango's discovery platform is based on synthetic lethality, which targets tumor suppressor gene loss that cannot be directly targeted due to their inactivation. This approach supplements existing therapies that focus on activated oncogenes [2][3] - **Pipeline Development**: Tango is advancing its lead asset, TNG-462, a PRMT5 inhibitor, which is synthetic lethal with MTAP deletions, common in lung and pancreatic cancers. The company is nearing the end of a Phase III study for this asset [8][9] - **Durability of Treatment**: The efficacy of TNG-462 is highlighted by its durability in patients, with some remaining on treatment for over a year, which is notable compared to standard chemotherapy options [10][11] - **Tolerability Profile**: TNG-462 is reported to have a best-in-class tolerability profile, making it suitable for patients with difficult-to-treat cancers [12] Pipeline Details - **TNG-462**: Focused on pancreatic and lung cancers, with plans to present data from over 20 patients in each category later this year [10] - **TNG-456**: A next-generation brain-penetrant asset aimed at glioblastoma, which has a high prevalence of MTAP deletions. This asset is expected to deliver more drug into the brain due to increased selectivity [13][15] - **TNG-260**: A coREST inhibitor targeting STK11 mutation patients, which represents a significant opportunity in non-small cell lung cancer. The program is currently in dose expansion [30][31] Competitive Landscape - **Key Competitors**: The primary competitors identified are Bristol Myers Squibb (BMS) and Amgen, with Tango believing it has a competitive edge in terms of pharmacokinetics (PK) and tolerability [21][22] - **Market Positioning**: Tango positions itself as a leader in the PRMT5 space, with a significant lead over other companies like AstraZeneca and BeiGene [22] Combination Strategies - **Combination with RAS Mutations**: Tango is initiating a study combining TNG-462 with RAS mutation-targeted therapies, which is expected to be transformative for pancreatic and lung cancer patients [27] - **Focus on Tolerability**: The company is monitoring overlapping toxicities in combination therapies but expects good tolerability based on existing safety profiles [29] Financial and Strategic Focus - **Capital Allocation**: Tango's capital allocation strategy is heavily focused on advancing the development of TNG-462 for pancreatic cancer, with plans to start a pivotal study next year [38] - **Investor Perception**: There is a belief that investors have underestimated the importance of PRMT5 as a target and Tango's position in the market. The company asserts it is well-resourced to compete effectively [36][37] Additional Insights - **Innovative Approach**: Tango's approach to synthetic lethality and its focus on specific genetic mutations (like STK11 and MTAP) are seen as innovative and potentially game-changing in oncology [30][31] - **Clinical Proof of Concept**: The company has demonstrated that its findings in animal models translate to human patients, reinforcing the validity of its therapeutic strategies [32][34]

Company Overview - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [3] - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related pathways [3] Upcoming Event - Barbara Weber, M.D., President and CEO of Tango Therapeutics, will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on June 10, 2025, from 3:20 to 3:55 PM ET [1] - The event will be available via live webcast on the company's website, with a replay accessible for 90 days post-presentation [2]

Core Insights - Tango Therapeutics has initiated the dosing of the first patient in the TNG456 Phase 1/2 trial targeting MTAP-deleted solid tumors, particularly glioblastoma (GBM) [1][2] - TNG456 is a next-generation PRMT5 inhibitor designed to penetrate the brain and is expected to offer a new treatment option for patients with GBM, where current survival rates are below 10% [2] - The trial aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of TNG456 both as a monotherapy and in combination with abemaciclib [2] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision cancer medicines [3] - The company employs the genetic principle of synthetic lethality to create therapies aimed at critical cancer targets [3]

Company Performance - Tango Therapeutics reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.34, and compared to a loss of $0.35 per share a year ago, indicating an earnings surprise of -5.88% [1] - The company posted revenues of $5.39 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 13.94%, and down from $6.47 million in the same quarter last year [2] - Over the last four quarters, Tango Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Tango Therapeutics shares have declined approximately 63.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $5.72 million, and for the current fiscal year, it is -$1.37 on revenues of $28.53 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Tango Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of ranked industries [8] - The performance of Tango Therapeutics may be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]